Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Djeha, AH; Thomson, TA; Leung, H; Searle, PF; Young, LS; Kerr, DJ; Harris, PA; Mountain, A; Wrighton, CJ
   Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors
   MOLECULAR THERAPY
   
   A.H. Djeha et al., "Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors", MOL THER, 3(2), 2001, pp. 233-240
2. Damen, EWP; de Groot, FMH; Scheeren, HW
   Novel anthracycline prodrugs
   EXPERT OPINION ON THERAPEUTIC PATENTS
   
   E.W.P. Damen et al., "Novel anthracycline prodrugs", EXPERT OP T, 11(4), 2001, pp. 651-666
3. Heine, D; Muller, R; Brusselbach, S
   Cell surface display of a lysosomal enzyme for extracellular gene-directedenzyme prodrug therapy
   GENE THERAPY
   
   D. Heine et al., "Cell surface display of a lysosomal enzyme for extracellular gene-directedenzyme prodrug therapy", GENE THER, 8(13), 2001, pp. 1005-1010
4. Plumb, JA; Bilsland, A; Kakani, R; Zhao, JQ; Glasspool, RM; Knox, RJ; Evans, TRJ; Keith, WN
   Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954
   ONCOGENE
   
   J.A. Plumb et al., "Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954", ONCOGENE, 20(53), 2001, pp. 7797-7803
5. Kan, O; Griffiths, L; Baban, D; Iqball, S; Uden, M; Spearman, H; Slingsby, J; Price, T; Esapa, M; Kingsman, S; Kingsman, A; Slade, A; Naylor, S
   Direct retroviral delivery of human cytochrome P4502B6 for gene-directed enzyme prodrug therapy of cancer
   CANCER GENE THERAPY
   
   O. Kan et al., "Direct retroviral delivery of human cytochrome P4502B6 for gene-directed enzyme prodrug therapy of cancer", CANC GENE T, 8(7), 2001, pp. 473-482
6. Denny, WA
   Prodrug strategies in cancer therapy
   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
   
   W.A. Denny, "Prodrug strategies in cancer therapy", EUR J MED C, 36(7-8), 2001, pp. 577-595
7. Folkes, LK; Wardman, P
   Oxidative activation of indole-3-acetic acids to cytotoxic species - a potential new role for plant auxins in cancer therapy
   BIOCHEMICAL PHARMACOLOGY
   
   L.K. Folkes e P. Wardman, "Oxidative activation of indole-3-acetic acids to cytotoxic species - a potential new role for plant auxins in cancer therapy", BIOCH PHARM, 61(2), 2001, pp. 129-136
8. Burke, PJ
   The potential use of carboxypeptidase G(2) in the treatment of cancer
   EXPERT OPINION ON THERAPEUTIC PATENTS
   
   P.J. Burke, "The potential use of carboxypeptidase G(2) in the treatment of cancer", EXPERT OP T, 10(2), 2000, pp. 209-214
9. Weyel, D; Sedlacek, HH; Muller, R; Brusselbach, S
   Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy
   GENE THERAPY
   
   D. Weyel et al., "Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy", GENE THER, 7(3), 2000, pp. 224-231
10. Greco, O; Patterson, AV; Dachs, GU
    Can gene therapy overcome the problem of hypoxia in radiotherapy?
    JOURNAL OF RADIATION RESEARCH
    
    O. Greco et al., "Can gene therapy overcome the problem of hypoxia in radiotherapy?", J RADIAT R, 41(3), 2000, pp. 201-212
11. Jaffar, M; Stratford, IJ
    Bioreductive drugs: selectivity towards hypoxic tissue
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    M. Jaffar e I.J. Stratford, "Bioreductive drugs: selectivity towards hypoxic tissue", EXPERT OP T, 9(10), 1999, pp. 1371-1380
12. Fonseca, MJ; Storm, G; Hennink, WE; Gerritsen, WR; Haisma, HJ
    Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy
    JOURNAL OF GENE MEDICINE
    
    M.J. Fonseca et al., "Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy", J GENE MED, 1(6), 1999, pp. 407-414
13. Bakina, E; Farquhar, D
    Intensely cytotoxic anthracycline prodrugs: galactosides
    ANTI-CANCER DRUG DESIGN
    
    E. Bakina e D. Farquhar, "Intensely cytotoxic anthracycline prodrugs: galactosides", ANTI-CAN DR, 14(6), 1999, pp. 507-515
14. Niculescu-Duvaz, I; Friedlos, F; Niculescu-Duvaz, D; Davies, L; Springer, CJ
    Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)
    ANTI-CANCER DRUG DESIGN
    
    I. Niculescu-Duvaz et al., "Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)", ANTI-CAN DR, 14(6), 1999, pp. 517-538
15. Hmphreys, MJ; Greenhalf, W; Neoptolemos, JP; Ghaneh, P
    The potential for gene therapy in pancreatic cancer
    INTERNATIONAL JOURNAL OF PANCREATOLOGY
    
    M.J. Hmphreys et al., "The potential for gene therapy in pancreatic cancer", INT J PANCR, 26(1), 1999, pp. 5-21
16. BLAKEY D
    ENZYME PRODRUG THERAPY OF CANCER
    Expert opinion on therapeutic patents
    
    D. Blakey, "ENZYME PRODRUG THERAPY OF CANCER", Expert opinion on therapeutic patents, 7(9), 1997, pp. 965-977
17. SIIM BG; DENNY WA; WILSON WR
    NITRO REDUCTION AS AN ELECTRONIC SWITCH FOR BIOREDUCTIVE DRUG ACTIVATION
    Oncology research
    
    B.G. Siim et al., "NITRO REDUCTION AS AN ELECTRONIC SWITCH FOR BIOREDUCTIVE DRUG ACTIVATION", Oncology research, 9(6-7), 1997, pp. 357-369
18. SHERWOOD RF
    ADVANCED DRUG-DELIVERY REVIEWS - ENZYME PRODRUG THERAPY
    Advanced drug delivery reviews
    
    R.F. Sherwood, "ADVANCED DRUG-DELIVERY REVIEWS - ENZYME PRODRUG THERAPY", Advanced drug delivery reviews, 22(3), 1996, pp. 269-288
19. SPRINGER CJ; NICULESCUDUVAZ I
    GENE-DIRECTED ENZYME PRODRUG THERAPY (GDEPT) - CHOICE OF PRODRUGS
    Advanced drug delivery reviews
    
    C.J. Springer e I. Niculescuduvaz, "GENE-DIRECTED ENZYME PRODRUG THERAPY (GDEPT) - CHOICE OF PRODRUGS", Advanced drug delivery reviews, 22(3), 1996, pp. 351-364
20. DENNY WA; WILSON WR; HAY MP
    RECENT DEVELOPMENTS IN THE DESIGN OF BIOREDUCTIVE DRUGS
    British Journal of Cancer
    
    W.A. Denny et al., "RECENT DEVELOPMENTS IN THE DESIGN OF BIOREDUCTIVE DRUGS", British Journal of Cancer, 74, 1996, pp. 32-38
21. CONNORS TA; KNOX RJ
    PRODRUGS IN CANCER-CHEMOTHERAPY
    Stem cells
    
    T.A. Connors e R.J. Knox, "PRODRUGS IN CANCER-CHEMOTHERAPY", Stem cells, 13(5), 1995, pp. 501-511
22. BRIDGEWATER JA; SPRINGER CJ; KNOX RJ; MINTON NP; MICHAEL NP; COLLINS MK
    EXPRESSION OF THE BACTERIAL NITROREDUCTASE ENZYME IN MAMMALIAN-CELLS RENDERS THEM SELECTIVELY SENSITIVE TO KILLING BY THE PRODRUG CB1954
    European journal of cancer
    
    J.A. Bridgewater et al., "EXPRESSION OF THE BACTERIAL NITROREDUCTASE ENZYME IN MAMMALIAN-CELLS RENDERS THEM SELECTIVELY SENSITIVE TO KILLING BY THE PRODRUG CB1954", European journal of cancer, 31A(13-14), 1995, pp. 2362-2370